Sensus Healthcare, Inc. (NASDAQ:SRTS): Are Analysts Optimistic?
Simply Wall St. · 1d ago
Athenex, Xtant Medical among major healthcare premarket losers' pack
Athenex ATNX -55% on Q4 earnings release and on FDA rejection of oral paclitaxel application in breast cancer.Xtant Medical Holdings (XTNT) -16%.PLx Pharma PLXP -9% after FDA OKs PLx Pharma's Vazalore applications.Lixte Biotechnology Holdings (LIXT) -12%.A...
Seekingalpha · 2d ago
DJ Sensus Healthcare Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
DJ Sensus Healthcare Price Target Raised to $6.00/Share From $4.00 by HC Wainwright & Co.
Dow Jones · 2d ago
Sensus Healthcare (SRTS) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Sensus Healthcare (SRTS) today and set a price target of $6.00. The company's shares closed
SmarterAnalyst · 2d ago
--Analyst Actions: HC Wainwright & Co. Adjusts Price Target on Sensus Healthcare to $6 From $4, Maintains Buy Rating
MT Newswires · 2d ago
DJ Sensus Healthcare, Inc. CEO Joe Sardano on Q4 2020 Results -- Earnings Call Transcript >SRTS
Dow Jones · 3d ago
Mid-Day Market Update: Nasdaq Rises Over 100 Points; Recro Pharma Shares Plummet
Midway through trading Friday, the Dow traded down 0.69% to 31,184.21 while the NASDAQ rose 0.95% to 13,243.64. The S&P also rose, gaining 0.21% to 3,837.28.
Benzinga · 5d ago
Xtant Medical, Sensus Healthcare leads healthcare gainers; Tricida, Recro Pharma among major losers
Gainers: Xtant Medical (XTNT) +54%, Sensus Healthcare (SRTS) +34%, Rubius Therapeutics (RUBY) +23%, Select Medical (SEM) +18%, Dynavax Technologies (DVAX) +18%.Losers: Tricida (TCDA) -32%, Recro Pharma (REPH) -27%, Zynex (ZYXI) -17%, NLS Pharmaceutics (NLS...
Seekingalpha · 5d ago
Mid-Morning Market Update: Markets Mostly Lower; Foot Locker Reports Mixed Q4 Results
Following the market opening Friday, the Dow traded down 0.99% to 31,089.98 while the NASDAQ rose 0.08% to 13,130.05. The S&P also fell, dropping 0.39% to 3,814.53.
Benzinga · 5d ago
DJ Sensus Healthcare Is Maintained at Buy by Roth Capital
Dow Jones · 5d ago
DJ Sensus Healthcare Price Target Raised to $6.00/Share From $4.00 by Roth Capital
Dow Jones · 5d ago
Sensus Healthcare Q4 Revenue Declines
MT Newswires · 5d ago
Sensus Healthcare Jumps After Posting Surprise Profit
Radiation-therapy-device specialist Sensus posted a surprise fourth-quarter profit of 6 cents a share. · 5d ago
Why Did Northland Securities Upgrade Sensus Healthcare’s Stock?
SmarterAnalyst · 5d ago
--Analyst Actions: Roth Capital Adjusts Price Target on Sensus Healthcare to $6 From $4, Maintains Buy Rating
MT Newswires · 5d ago
BRIEF-Sensus Healthcare Reports Q4 And Full Year 2020 Financial Results · 5d ago
Sensus Healthcare Q4 EPS $0.06 Beats $(0.11) Estimate, Sales $5.09M Beat $2.53M Estimate
Sensus Healthcare (NASDAQ:SRTS) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.11) by 154.55 percent. This is unchanged from the same period last year. The company
Benzinga · 6d ago
Sensus Healthcare EPS beats by $0.17, beats on revenue
Sensus Healthcare (SRTS): Q4 GAAP EPS of $0.06 beats by $0.17.Revenue of $5.09M (-40.2% Y/Y) beats by $2.56M.Adjusted EBITDA, a non-GAAP financial measure, was $1.3M for both Q4 of 2020
Seekingalpha · 6d ago
Sensus Healthcare 4Q Net $1M >SRTS
Sensus Healthcare 4Q Net $1M >SRTS
Dow Jones · 6d ago
Webull provides a variety of real-time SRTS stock news. You can receive the latest news about Sensus Hlthcr through multiple platforms. This information may help you make smarter investment decisions.
About SRTS
Sensus Healthcare, Inc. is a medical device company. The Company is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. It uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The Company incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100 Plus and SRT-100 Vision. The Company's product, the SRT-100, is a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions, such as keloids. The SRT-100 treats primary lesions in the sensitive areas of the head and neck region. Its Sensus Laser Aesthetic Solutions division provides a range of in-office aesthetic dermatology procedures including facial rejuvenation, wrinkle removal, body sculpting/fat removal as well as other aesthetic applications.